<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331018</url>
  </required_header>
  <id_info>
    <org_study_id>2097.00</org_study_id>
    <secondary_id>NCI-2011-00202</secondary_id>
    <secondary_id>2097.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01331018</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Fanconi Anemia</brief_title>
  <official_title>Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rocket Pharma Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial will access the toxicity and efficacy of infusion of gene modified
      cells for patients with Fanconi anemia (FA). Infusion of autologous patient blood stem cells
      that have been corrected in the laboratory by introduction of the normal gene may improve
      blood counts in patients with FA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety of lentiviral gene transfer for patients with Fanconi anemia
      complementation group A.

      SECONDARY OBJECTIVES:

      I. To determine the feasibility and efficacy of filgrastim (G-CSF) and plerixafor
      mobilization in FA patients.

      II. To determine the feasibility and efficacy of lineage depletion of bone marrow or
      mobilized apheresis product.

      III. To determine the transduction efficiency for human FA patient hematopoietic progenitor
      cells transduced with a clinical grade lentiviral vector encoding the gene for Fanconi anemia
      complementation group A.

      IV. To determine if gene transfer using the clinical grade vector will result in phenotypic
      correction of gene modified cells by in vitro assays.

      V. To determine if infusion of FANCA gene-modified cells will result in engraftment and
      persistence of gene-modified cells and improvement in blood counts in FA patients.

      OUTLINE:

      STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim subcutaneously (SC)
      twice daily (BID) for 5-6 days (on days 1-6 of mobilization). Patients receive plerixafor SC
      once daily (QD) on days 4-6 of mobilization. Peripheral blood stem cell (PBSC) count will be
      checked daily starting on day 4 of mobilization. Patients who have a PBSC count of &gt;= 5 CD34+
      cells/mcL will undergo up to 2 apheresis collections on consecutive days.

      BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone
      marrow harvest for collection of stem/progenitor cells.

      REINFUSION: Patients receive methylprednisolone intravenously (IV) or prednisone orally (PO)
      on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of
      genetically modified hematopoietic stem/progenitor cells on day 0.

      After completion of study treatment, patients are followed up periodically for 15 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2012</start_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematological and non-hematological organ toxicity</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Adverse events will be graded by Common Terminology Criteria for Adverse Events (CTCAE), version 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of insertional mutagenesis or hematologic malignancy</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Adverse events will be graded by CTCAE, version 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of replication competent lentivirus</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Adverse events will be graded by CTCAE, version 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of G-CSF and plerixafor mobilization in Fanconi anemia (FA) patients</measure>
    <time_frame>Up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lineage depletion of bone marrow or mobilized cell product</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transduction efficiency</measure>
    <time_frame>Day 0</time_frame>
    <description>After completion of lentiviral transduction, the percent gene modified cells will be determined by molecular studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detectable levels of transduced cells in blood and marrow</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Blood and bone marrow samples will be assayed by real-time quantitative polymerase chain reaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved blood counts</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Complete blood counts will be monitored, initially weekly, then monthly during the first year, then quarterly during the 2nd year after infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstrable functional expression by growth of recipient cells in mitomycin C</measure>
    <time_frame>3 months</time_frame>
    <description>Blood and bone marrow cells will be assayed for viability of cultured cells and hematopoietic colonies in the presence of the chemotherapy drug and deoxyribonucleic acid crosslinking agent, mitomycin C.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment (hematopoietic stem progenitor cells)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim SC BID for 5-6 days (on days 1-6 of mobilization). Patients receive plerixafor SC QD on days 4-6 of mobilization. PBSC count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of &gt;= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days.
BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells.
REINFUSION: Patients receive methylprednisolone IV or prednisone PO on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Aspiration</intervention_name>
    <description>Undergo bone marrow harvest</description>
    <arm_group_label>Treatment (hematopoietic stem progenitor cells)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (hematopoietic stem progenitor cells)</arm_group_label>
    <other_name>FILGRASTIM, LICENSE HOLDER UNSPECIFIED</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Genetically Engineered Hematopoietic Stem Progenitor Cells</intervention_name>
    <description>Undergo infusion of genetically modified hematopoietic progenitor cell therapy</description>
    <arm_group_label>Treatment (hematopoietic stem progenitor cells)</arm_group_label>
    <other_name>Genetically Engineered HSPCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (hematopoietic stem progenitor cells)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>Undergo leukapheresis</description>
    <arm_group_label>Treatment (hematopoietic stem progenitor cells)</arm_group_label>
    <other_name>Leukocytopheresis</other_name>
    <other_name>Therapeutic Leukopheresis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (hematopoietic stem progenitor cells)</arm_group_label>
    <other_name>Adlone</other_name>
    <other_name>Caberdelta M</other_name>
    <other_name>DepMedalone</other_name>
    <other_name>Depo Moderin</other_name>
    <other_name>Depo-Nisolone</other_name>
    <other_name>Duralone</other_name>
    <other_name>Emmetipi</other_name>
    <other_name>Esametone</other_name>
    <other_name>Firmacort</other_name>
    <other_name>Medlone 21</other_name>
    <other_name>Medrate</other_name>
    <other_name>Medrol</other_name>
    <other_name>Medrol Veriderm</other_name>
    <other_name>Medrone</other_name>
    <other_name>Mega-Star</other_name>
    <other_name>Meprolone</other_name>
    <other_name>Methylprednisolonum</other_name>
    <other_name>Metilbetasone Solubile</other_name>
    <other_name>Metrocort</other_name>
    <other_name>Metypresol</other_name>
    <other_name>Metysolon</other_name>
    <other_name>Predni-M-Tablinen</other_name>
    <other_name>Prednilen</other_name>
    <other_name>Radilem</other_name>
    <other_name>Sieropresol</other_name>
    <other_name>Solpredone</other_name>
    <other_name>Summicort</other_name>
    <other_name>Urbason</other_name>
    <other_name>Veriderm Medrol</other_name>
    <other_name>Wyacort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (hematopoietic stem progenitor cells)</arm_group_label>
    <other_name>AMD 3100</other_name>
    <other_name>JM-3100</other_name>
    <other_name>Mozobil</other_name>
    <other_name>SDZ SID 791</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (hematopoietic stem progenitor cells)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FA demonstrated by a positive test for increased sensitivity to chromosomal breakage
             with mitomycin C or diepoxybutane performed by a Clinical Laboratory Improvement
             Amendments (CLIA) or College of American Pathologists (CAP) approved laboratory

          -  FA complementation group A as determined by somatic cell hybrids, molecular
             characterization, western blot analysis, acquisition of mitomycin C resistance after
             in vitro lentiviral transduction with a vector bearing the complementary
             deoxyribonucleic acid (cDNA) for Fanconi complementation group A, or other clinically
             certified method of complementation group analysis

          -  Bone marrow analysis demonstrating normal cytogenetics, and no more than 5% of cells
             with a single clonal abnormality by fluorescence in situ hybridization (FISH) for
             myelodysplastic syndrome (MDS) panel within 3 months of stem cell collection

          -  Signed informed consent by the patient or legally authorized representative

          -  Absolute neutrophil count &gt;= 0.5 x 10^9/L

          -  Hemoglobin &gt;= 8 g/dL

          -  Platelet count &gt;= 20 x 10^9/L and able to achieve a platelet count of &gt;= 50 x 10^9/L
             with transfusion support

          -  Adequate hepatic function with aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT) &lt; 5 x upper limit of normal (ULN)

          -  Adequate renal function with creatinine (Cre) =&lt; 1.5; if greater, then glomerular
             filtration rate (GFR) &gt; 60 mL/min/1.73 m^2 as calculated by the Modification of Diet
             in Renal Disease equation

          -  Adequate pulmonary function with corrected diffusion capacity of carbon monoxide
             (DLCO) &gt; 50% in those for whom this study can be performed

          -  For subjects &lt; 17 years of age, Modified Lansky Play-Performance Score of &gt;= 70%; for
             subjects 17 and older, Karnofsky score of &gt;= 70%

        Exclusion Criteria:

          -  Non-hematopoietic malignancy where the expected survival is less than 2 years

          -  Myelodysplastic syndrome as defined by World Health Organization (WHO) criteria

          -  Acute myeloid leukemia as defined by WHO criteria

          -  Pregnancy or lactation; females of childbearing potential and males who are admitted
             to the study will be advised that the study procedures and study drugs may be
             teratogenic, and they will be required to take adequate measures to prevent conception
             for the duration of the study

          -  Concurrent enrollment in any other study using an investigational drug

          -  Physical or emotional status that would prevent informed consent, protocol compliance,
             or adequate follow-up

          -  Patients for whom an human leukocyte antigen (HLA) matched sibling donor bone marrow
             transplant is being actively pursued will not be eligible for study until it is
             determined that no sibling donor is available or that a stem cell transplant is not
             feasible during the time the patient might be on study

               -  No patient will be included in this study as an alternative to a clinically
                  indicated HLA matched sibling donor stem cell transplant

               -  If an HLA matched sibling donor is identified, but stem cell or marrow collection
                  is not feasible (e.g., donor is in utero, is a newborn from whom cord blood was
                  not collected, or is unable to undergo a donation procedure because of ill
                  health), a patient may be included in the study at the discretion of the
                  investigators

          -  Significant associated diseases including documented human immunodeficiency virus
             (HIV) infection, uncontrolled hypertension (diastolic blood pressures &gt; 95%ile for
             age), unstable angina, congestive heart failure (&gt; New York [NY] class II), poorly
             controlled diabetes (hemoglobin A1c [Hgb A1c] &gt; 7%), coronary angioplasty within 6
             months, myocardial infarction within the last 6 months, or uncontrolled atrial or
             ventricular cardiac arrhythmia, abnormal coagulation, persistent abnormal urinalysis
             reflecting intrinsic renal disease

          -  Active ongoing viral, bacterial, or fungal infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Becker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela S. Becker</last_name>
      <phone>206-288-7234</phone>
      <email>pbecker@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela S. Becker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

